Center-Authored Papers

Filters: Author is Zelenetz, Andrew D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
World Health Organization
Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH et al..  2011.  NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.. Journal of the National Comprehensive Cancer Network : JNCCN. 9 Suppl 4:S1-22. Abstract
Whole-Body Irradiation
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
United States
Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH et al..  2011.  NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.. Journal of the National Comprehensive Cancer Network : JNCCN. 9 Suppl 4:S1-22. Abstract
Treatment Outcome
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
Time Factors
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
Stem Cell Transplantation
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
September 2011
Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, McLaughlin P, Press OW, Zelenetz AD.  2011.  Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.. Leukemia & lymphoma. 52(7):1188-99. Abstract
Retrospective Studies
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
Remission Induction
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
RECURRENCE
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2014.  Non-Hodgkin's lymphomas, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(9):1282-303. Abstract
Radiometry
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
Radioimmunotherapy
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
Neoplasms
Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH et al..  2011.  NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.. Journal of the National Comprehensive Cancer Network : JNCCN. 9 Suppl 4:S1-22. Abstract
Neoplasm Staging
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP et al..  2010.  NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(3):288-334.
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2014.  Non-Hodgkin's lymphomas, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(9):1282-303. Abstract
Myelodysplastic Syndromes
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
Multivariate Analysis
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
Models, Statistical
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
Middle Aged
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
Male
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM et al..  2005.  Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.. Blood. 105(12):4576-82. Abstract
Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ et al..  2014.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.. Blood. 124(15):2354-61. Abstract
Lymphoma, Non-Hodgkin
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis BC, Bartlett N, Byrd JC, Czuczman MS, Fayad LE et al..  2014.  Non-Hodgkin's lymphomas, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(9):1282-303. Abstract